巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    虛擬市場

    Lantern Pharma

    LTRN
    5.560
    ▼0.350
    ▼5.92%
    概況消息
    最少15分鐘延遲，股票資訊由第三方資訊供應商提供
    ・Lantern Pharma - 延遲價格・最後更新於 27/05 2:38
    最高位
    5.810
    最低位
    5.540
    開市價
    --
    前收市價
    5.910
    成交量(千)
    0.04
    成交額(百萬)
    0.00
    買入
    5.630
    賣出
    5.930
    每手股數
    --
    市值(百萬)
    60.22
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    16.500 - 4.998
    所有資料不保證絕對正確、完整、或實時，僅作為參考使用。投資涉及風險，過往業績並不代表將來表現，作任何投資決定或交易前，閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Lantern Pharma
    證券代碼
    LTRN.US
    所屬板塊
    Biotechnology
    公司業務
    Lantern Pharma Inc is a clinical-stage biotechnology company. It is focused on leveraging artificial intelligence (A.I), machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from targeted oncology therapies. The firm's pipeline of development programs involves four drug candidates and an Antibody Drug Conjugate (ADC) program directed towards eight therapeutic targets. Its A.I. platform, known as RADR, includes more than 18 billion data points, and uses big data analytics and machine learning to rapidly uncover biologically relevant genomic signatures correlated to drug response, and then identify the cancer patients that we believe may benefit most from our compounds.
    發行量
    10780490
    公司總部
    1920 McKinney Avenue, 7th Floor
    公司網址
    https://www.lanternpharma.com
    公司電話
    +1 972 277-1136

    最新發佈

    暫無內容

    關於

    Lantern Pharma(LTRN.US)所屬的行業板塊為Biotechnology。
    Lantern Pharma Inc is a clinical-stage biotechnology company. It is focused on leveraging artificial intelligence (A.I), machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from targeted oncology therapies. The firm's pipeline of development programs involves four drug candidates and an Antibody Drug Conjugate (ADC) program directed towards eight therapeutic targets. Its A.I. platform, known as RADR, includes more than 18 billion data points, and uses big data analytics and machine learning to rapidly uncover biologically relevant genomic signatures correlated to drug response, and then identify the cancer patients that we believe may benefit most from our compounds.
    詳細公司背景可參考: https://www.lanternpharma.com。